1. Academic Validation
  2. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance

  • Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. doi: 10.1128/AAC.00016-14.
Udayan Chatterji 1 Jose A Garcia-Rivera 1 James Baugh 1 Katarzyna Gawlik 1 Kelly A Wong 2 Weidong Zhong 2 Clifford A Brass 3 Nikolai V Naoumov 4 Philippe A Gallay 5
Affiliations

Affiliations

  • 1 Department of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, USA.
  • 2 Novartis Institutes for BioMedical Research, Emeryville, California, USA.
  • 3 Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • 4 Novartis Pharma AG, Basel, Switzerland.
  • 5 Department of Immunology & Microbial Science, The Scripps Research Institute, La Jolla, California, USA gallay@scripps.edu.
Abstract

Alisporivir (ALV), a Cyclophilin Inhibitor, is a host-targeting Antiviral (HTA) with multigenotypic anti-hepatitis C virus (HCV) activity and a high barrier to resistance. Recent advances have supported the concept of interferon (IFN)-free regimens to treat chronic hepatitis C. As the most advanced oral HTA, ALV with direct-acting antivirals (DAAs) represents an attractive drug combination for IFN-free therapy. In this study, we investigated whether particular DAAs exhibit additive, synergistic, or antagonistic effects when combined with ALV. Drug combinations of ALV with NS3 Protease, NS5B polymerase, and NS5A inhibitors were investigated in HCV replicons from genotypes 1a, 1b, 2a, 3, and 4a (GT1a to -4a). Combinations of ALV with DAAs exerted an additive effect on GT1 and -4. A significant and specific synergistic effect was observed with ALV-NS5A inhibitor combination on GT2 and -3. Furthermore, ALV was fully active against DAA-resistant variants, and ALV-resistant variants were fully susceptible to DAAs. ALV blocks the contact between Cyclophilin A and domain II of NS5A, and NS5A inhibitors target domain I of NS5A; our data suggest a molecular basis for the use of these two classes of inhibitors acting on two distinct domains of NS5A. These results provide in vitro evidence that ALV with NS5A inhibitor combination represents an attractive strategy and a potentially effective IFN-free regimen for treatment of patients with chronic hepatitis C. Due to its high barrier and lack of cross-resistance, ALV could be a cornerstone drug partner for DAAs.

Figures
Products